Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Change in body weight (absolute) from Baseline

Time frame: Baseline and week 76

Percentage of participants who achieve ≥5% reduction in body weight

Time frame: Baseline and week 76

Percentage of participants who achieve ≥10% reduction in body weight

Time frame: Baseline and week 76

Percentage of participants who achieve ≥15% reduction in body weight

Time frame: Baseline and week 76

Percentage of participants who achieve ≥20% reduction in body weight

Time frame: Baseline and week 76

Change in waist circumference from Baseline

Time frame: Baseline and week 76

Change in resting systolic blood pressure from Baseline

Time frame: Baseline and week 76

Percent change in fasting triglycerides and non-HDL cholesterol from Baseline

Time frame: Baseline and week 76

Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version physical function from Baseline

Time frame: Baseline and week 76

Change in HbA1c from Baseline

Time frame: Baseline and week 76

Change in body mass index from Baseline

Time frame: Baseline and week 76

Percent change in fasting total cholesterol from Baseline

Time frame: Baseline and week 76

Change in fasting glucose from Baseline

Time frame: Baseline and week 76

Change in resting diastolic blood pressure from Baseline

Time frame: Baseline and week 76